Equities

NextCell Pharma AB

NextCell Pharma AB

Actions
  • Price (SEK)1.77
  • Today's Change0.10 / 5.99%
  • Shares traded371.52k
  • 1 Year change-34.29%
  • Beta1.3225
Data delayed at least 15 minutes, as of Sep 20 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Aug 31 2023202320222021
ASSETS
Cash And Short Term Investments5097139
Total Receivables, Net3.582.711.70
Total Inventory0.790.77--
Prepaid expenses136.165.61
Other current assets, total0----
Total current assets67107146
Property, plant & equipment, net149.902.90
Goodwill, net------
Intangibles, net------
Long term investments6.876.875.11
Note receivable - long term1.131.131.13
Other long term assets00--
Total assets89125156
LIABILITIES
Accounts payable0.891.921.28
Accrued expenses7.844.162.05
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total1.350.850.63
Total current liabilities106.933.96
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total3.022.181.58
Total liabilities139.125.53
SHAREHOLDERS EQUITY
Common stock7.057.057.05
Additional paid-in capital------
Retained earnings (accumulated deficit)69108143
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity76116150
Total liabilities & shareholders' equity89125156
Total common shares outstanding444444
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.